Composition for treating viral infections comprising extracellular vesicles derived from mesenchymal stem cells and alpha-1 antitrypsin
Patent Information
- Application Number
- JP2023527970
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-02-26
- Filing Date
- 2021-11-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for viral infections, particularly those caused by coronaviruses like SARS-CoV-2, lack effective alternatives that can modulate the immune response and prevent viral entry into host cells while minimizing harmful inflammation and tissue damage.
A pharmaceutical composition combining extracellular vesicles derived from mesenchymal stem cells (MSCs) with alpha-1 antitrypsin (AAT) proteins, which synergistically enhance immune modulation and inhibit viral infection, administered topically or locally to mucosal surfaces to treat and prevent viral infections.
The combination of MSC-derived extracellular vesicles and AAT proteins effectively reduces cytokine storms, prevents viral entry, and promotes an appropriate immune response, offering enhanced protection against viral infections with reduced systemic side effects.
Abstract
Description
Technical Field
[0001] The present invention is in the field of compositions and delivery systems for pharmaceuticals for treating viral infections in a subject. The present invention relates to a pharmaceutical composition comprising extracellular vesicles isolated from mesenchymal stem cells (MSCs) and alpha-1 antitrypsin (AAT) protein for use as a pharmaceutical in the treatment and / or prevention of viral infections in a human subject. Further, the present invention relates to a composition for topical and / or local administration to the mucosal surface of the subject's airway and / or into the oral cavity. In another aspect, the present invention relates to a delivery system and corresponding formulations for dispensing the pharmaceutical composition.
Background Art
[0002] Mesenchymal stem cells (MSCs) are cells of non-hematopoietic origin present in bone marrow and other tissues. MSCs are generally considered to be multipotent adult progenitor cells with the ability to differentiate into a limited number of cell lineages such as osteoblasts, chondrocytes, adipocytes. Research has been conducted on the use of MSCs as therapeutic entities based on their ability to directly differentiate into these end-stage phenotypes, which includes using MSCs to promote or enhance bone repair and repair cartilage defects (Non-Patent Documents 1 and 2). The isolation and culture of MSCs for many therapeutic applications have been described, representing a promising approach for the treatment of inflammation-related disorders (for example, Patent Document 1).
[0003] MSCs interact with most cell types of the innate and adaptive immune systems, including B cells, T cells, dendritic cells (DCs), natural killer (NK) cells, neutrophils, macrophages, and mitigate the response to pathogens. MSCs also play a role in the control of tissue inflammation. The therapeutic effects of MSCs are thought to be mainly due to the secretion of immunomodulatory factors and regenerative factors, and some of their effects may be mediated through host phagocytic cells that remove the administered MSCs and adapt to immunomodulatory and regenerative support functions in the process.
[0004] In response to inflammatory factors such as interferon (IFNg) and tumor necrosis factor (TNFα) secreted by activated immune and tissue cells, MSCs can take the form of immunomodulatory phenotypes. They increase the expression of anti-inflammatory factors, including programmed death ligand 1 and prostaglandin E2, and inhibit immune cell activity and proliferation through metabolic regulation, such as the indole-amine 2,3-dioxygenase-dependent catabolism of tryptophan. MSCs also express ATPase and possess ectonucleotidase activity through CD73 expression, which allows them to deplete ATP. The immunomodulatory effects of MSCs may be further triggered by activation of TLR receptors in MSCs stimulated by pathogen-associated molecules such as LPS. Importantly, MSCs lack ACE2 receptors and are therefore resistant to SARS-CoV-2 infection (Non-Patent Literature 3).
[0005] MSCs are thought to exert their therapeutic effects through the secretion of factors that mitigate cell damage and promote repair. The therapeutic effects of MSCs may be mediated by paracrine factors, including extracellular vesicles such as exosomes, which are nanometer-sized membrane-bound vesicles that function as mediators of intercellular communication. Extracellular vesicles derived from MSCs include cytokines and growth factors, signaling lipids, mRNA, and regulatory miRNAs. Growing evidence suggests that MSC-derived exosomes may represent a novel cell-free therapy with attractive advantages over parental MSCs, such as no risk of tumorigenesis and low immunogenicity. Nevertheless, the precise mechanisms of in vivo action of exogenously administered exosomes, their distribution in the body, pharmacokinetics, and potential for targeted delivery remain not fully understood (Non-Patent Literature 4).
[0006] Severe Acute Respiratory Syndrome (SARS) is a coronavirus (CoV)-borne respiratory illness first observed in 2002. Based on scientific reports, it is assumed that all human CoVs may originate from zoonotic diseases. Once humans are infected, the virus spreads rapidly through droplet transmission and close contact between people, leading to epidemic scenarios and even pandemics. As an example, "Coronavirus Disease 2019" (COVID-19) is caused by the pathogenic coronavirus SARS-CoV-2. Starting in December 2019, the virus spread worldwide in weeks, causing an international health emergency. A global pandemic presents significant challenges to healthcare systems and leads to restrictions on social life and weakening of the global market economy. To date, there is no effective treatment, and the disease is associated with high morbidity and mortality rates, making therapeutic interventions for those affected and preventive measures to contain outbreaks extremely important.
[0007] Recent reports are investigating the potential use of bone marrow mesenchymal stem cell-derived exosomes as a treatment for severe COVID-19. Because the immune system is central to infection, it is essential to balance the immune response to prevent potentially aggravated and harmful immune responses that could lead to multi-organ damage. MSCs and MSC exosomes possess immunomodulatory functions and can influence immune cells by inducing anti-inflammatory macrophages, regulatory T cells and regulatory B cells, as well as regulatory dendritic cells, and can inactivate T cells, thus potentially making them useful as a therapeutic tool to balance the immune response in patients with acute COVID-19 (Non-Patent Documents 5, 6, and 7).
[0008] Alpha-1 antitrypsin (also known as A1AT, AAT, PI, or SERPINA1) is a glycoprotein of 52 kDa or greater, and one of the most abundant endogenous serine protease inhibitors (SERPIN superfamily). AAT is considered an acute-phase protein, and its levels can increase several-fold during acute inflammation.
[0009] While primarily known for its antiprotease and anti-inflammatory activity, studies conducted over the past decade have cumulatively demonstrated that AAT is also an immunomodulator and cytoprotective molecule. Thus, studies have shown that AAT-rich microenvironments reduce levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α, while increasing levels of anti-inflammatory mediators such as IL-1 receptor antagonists and IL-10. This phenomenon has been demonstrated in in vitro studies of human PBMCs, as well as in samples obtained from cystic fibrosis patients treated with inhaled AAT. Simultaneously, AAT has been shown to directly bind to IL-8 and risk-associated molecular pattern molecules (DAMPs) such as extracellular HSP70 and gp96, otherwise acting as an adjuvant to the relevant immune response (Non-Patent Literature 8).
[0010] Remarkably, the anti-inflammatory effects of AAT enable innate immune cells to respond to a real threat, with macrophages readily phagocytosing bacteria, neutrophils decontaminating the infection site, and antigen-loaded dendritic cells migrating to excretory lymph nodes. Meanwhile, T lymphocytes respond indirectly to the AAT-rich environment, waiting for stimulation from innate immune cells. For example, AAT has been shown to induce semi-mature antigen-presenting cells that promote the proliferation of protective regulatory T cells. B lymphocytes, belonging to both the innate and adaptive immune systems, are thought to exert a modified response in the presence of AAT in the form of reduced isotype switching, resulting in enhanced protective IgM production. For example, as seen in CF patients, the reduction in bacterial load during AAT treatment may be associated with an enhanced anti-pathogen immune response, while simultaneously suggesting that local tissues are spared from inappropriate excessive damage that could promote a harmful adaptive response by increasing local DAMP levels (Non-Patent Literature 9).
[0011] Alpha-1 antitrypsin deficiency (AATD, or 1-antitrypsin deficiency, or A1AD) is a disorder that causes insufficient production of alpha-1 antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and excessive deposition of abnormal A1AT protein in hepatocytes. There are more than 75 known different mutations in SERPINA1, and 90% of alpha-1 antitrypsin deficiency cases are due to the PI*Z missense mutation Glu342Lys. AAT deficiency leads to unsuppressed chronic tissue destruction, allowing neutrophil elastases to freely degrade alveolar interstitial elastin, causing respiratory complications such as airway inflammation and emphysema. According to a May 2020 report by Vianello, AATD, the most common genetic disorder in adults, is most prevalent in northern Italy and decreases significantly from north to south. Recent data from the Italian AATD registry shows that the geographical distribution of confirmed cases is very similar to that reported for SARS-CoV-2 infections, accounting for 47% (237 out of 508) of the total registered in the Lombardy region.
[0012] Reports indicate that AAT production increases in COVID-19, but this anti-inflammatory response is overwhelmed in severe cases (Non-Patent Literature 10). SARS-CoV-2 entry into infected cells is mediated by the binding of the viral spike protein to human angiotensin-converting enzyme-2 (ACE2) target receptors via its receptor-binding domain (RBD). Blocking this interaction, for example, by human antibodies leads to the neutralization of the virus in patients and subsequent recovery from infection. Further studies have also shown that SARS-CoV-2 entry is facilitated by endogenous and exogenous proteases. These proteases proteolytically activate the SARS-CoV-2 spike glycoprotein and are important modulators of virtropy. AAT has been identified as an abundant serum protease inhibitor that strongly restricts protease-mediated SARS-CoV-2 entry. In vitro inhibition of protease-mediated SARS-CoV-2 entry by AAT occurs at concentrations lower than those present in serum and bronchoalveolar tissue, suggesting a physiologically related effect of AAT (Non-Patent Literature 11).
[0013] Despite these advances, to the best of our knowledge, the use of MSC-derived extracellular vesicles to prevent viral infection has not been proposed in the art until now. Previous reports have focused on the treatment of acute COVID disease and the regulation of undesirable hyperactivity of the immune response using MSC exosomes. Furthermore, to the best of our knowledge, the combination of MSC-derived extracellular vesicles with AAT administration for the treatment and / or prevention of viral infection has not been proposed in the art until now. [Prior art documents] [Patent Documents]
[0014] [Patent Document 1] WO 2010 / 119039 [Non-patent literature]
[0015] [Non-licensed document 1] Vilquin and Rosset, Regenerative Medicine2006: 1, 4, p 589 [Non-licensed document 2] Veronesi et al, Stem Cells and Development2013; 22, p 18 1 [Non-licensed document 3] International Society for InfectiousDiseases, international journal of infectious disease, 2020, p433
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Summary of the Invention
Problems to be Solved by the Invention
[0016] In light of the prior art, the technical problem underlying the present invention is to provide alternative and / or improved means for the treatment of viral infections.
Means for Solving the Problems
[0017] This problem is solved by the features of the independent claims of the present invention. Preferred embodiments of the present invention are provided by the dependent claims.
[0018] Thus, the present invention relates to a pharmaceutical composition comprising extracellular vesicles isolated from mesenchymal stem cells (MSCs) and alpha-1 antitrypsin (AAT) protein for use as a pharmaceutical in the treatment and / or prevention of viral infections in a human subject.
[0019] AAT has a tissue anti-inflammatory effect and local activity in lung tissue. Advantageously, due to the anti-inflammatory property of AAT, innate immune cells can respond to a real threat; macrophages can easily phagocytize bacteria, neutrophils can decontaminate the infection site, and antigen-loaded dendritic cells can migrate to draining lymph nodes. Thus, AAT can exert multiple effects such as reducing unwanted cytokine storms caused by inflammation and viral infection while enabling an effective immune response against pathogens, and it is considered that AAT can also actively inhibit viral infections, particularly viral infections caused by SARS-CoV-2. Since proteases are known to activate the SARS-CoV-2 spike glycoprotein, AAT is a serum protease inhibitor that can limit the entry of SARS-CoV-2 via proteases.
[0020] MSCs are thought to exert anti-inflammatory and immunomodulatory functions, promoting the regeneration of damaged tissue and inhibiting tissue fibrosis. The immunomodulatory effects of MSCs include direct and indirect effects on host immune cells. The therapeutic effects of MSCs are partially mediated by the secretion of factors containing extracellular vesicles, such as MSC-derived exosomes, and there is a promising potential for using MSC exosomes to modulate the immune response in SARS-CoV-2 infection.
[0021] Therefore, the combination of extracellular vesicles isolated from mesenchymal stem cells (MSCs) and the alpha-1 antitrypsin (AAT) protein represents a beneficial approach for achieving a combined effect of immunomodulation during infection and limitation of viral infection in target cells.
[0022] Surprisingly, the combination of extracellular vesicles isolated from MSCs and AAT protein leads to enhanced prevention of viral infection and / or enhancement of the immune response to infection in target cells, which is greater than the combined effect achieved by either drug when administered alone. In some embodiments, the combined effect of extracellular vesicles isolated from MSCs and AAT protein is synergistic in preventing viral infection and / or enhancing the immune response to infection in target cells. In some embodiments, the combined effect of extracellular vesicles isolated from MSCs and AAT protein represents previously unsuggested technical effects in immunomodulation during infection and limiting viral infection in target cells. In some embodiments, this favorable synergy represents a novel approach to preventing viral infection.
[0023] According to the inventors' knowledge, no pharmaceutical composition comprising extracellular vesicles isolated from mesenchymal stem cells and alpha-1 antitrypsin protein had been previously proposed for the treatment / prevention of viral infections in human subjects. It was particularly surprising that a pharmaceutical composition comprising extracellular vesicles isolated from mesenchymal stem cells and alpha-1 antitrypsin protein could treat and / or prevent viral infections in human subjects.
[0024] In one embodiment, the AAT protein is an isolated AAT protein added to the composition. For example, AAT may be a recombinant AAT protein, or a purified AAT protein, for example, purified from human plasma, which may then be added to the composition for final combination with extracellular vesicles. In one embodiment, the AAT protein may be produced in the MSC from which the extracellular vesicles are isolated. In one embodiment, the AAT protein is endogenous to the MSC from which the extracellular vesicles are obtained. This means that the AAT protein is expressed from the original gene and promoter (for example, from an unmodified MSC).
[0025] In one embodiment, the AAT protein is an exogenous protein. In one embodiment, AAT is exogenous to MSCs from which extracellular vesicles have been obtained. For example, a trans gene encoding AAT can be expressed from MSCs to obtain, for example, a large amount of AAT expression, and the extracellular vesicles contain AAT, preferably in a relatively larger amount, for example, more than the amount of AAT in extracellular vesicles obtained from unmodified MSCs.
[0026] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment and / or prevention of viral infection in human subjects, wherein the AAT protein is expressed in mesenchymal stem cells (MSCs) from which extracellular vesicles are isolated, and the MSCs are genetically modified to express exogenous alpha-1 antitrypsin (AAT).
[0027] In this embodiment, AAT is supplied to the extracellular vesicles, either within or accompanying them, preferably by transgenic (exogenous) AAT expression in MSCs from which extracellular vesicles have been obtained. Surprisingly beneficially, the AAT produced by transgenic expression in modified MSCs is present in the extracellular vesicles in considerable amounts suitable for enhancing the antiviral effect. In some embodiments, exogenous AAT is generated from an endogenous coding region / gene, but is generated by expression via a modified promoter with a higher expression level.
[0028] In some embodiments, both extracellular vesicles and alpha-1 antitrypsin (AAT) are obtained from mesenchymal stem cells (MSCs) that have been genetically modified to express exogenous alpha-1 antitrypsin (AAT). This combination yields remarkable effects in treating / preventing viral infections in human subjects.
[0029] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment and / or prevention of viral infections in human subjects, the composition being rich in alpha-1 antitrypsin (AAT) protein, preferably rich in isolated recombinant AAT protein.
[0030] Therefore, isolated AAT proteins can be added to extracellular vesicles derived from MSCs, either from extracellular vesicles of unmodified MSCs or from modified AATs expressing transgenic AAT.
[0031] AAT can be generated by recombination in a variety of systems, including bacterial, insect, or mammalian cells. Recombinantly generated AAT has post-translational modifications, preferably distinct glycosylations, more preferably N-glycosylation and / or O-glycosylation. Changes in the glycosylation pattern of AAT primarily affect the rate of proteolysis in both the endoplasmic reticulum and plasma, and the rate at which the protein aggregates. These factors extend the plasma half-life of the AAT protein from 7 minutes to 1 day, preferably 2 days, more preferably 3 to 4 days. Therefore, in some embodiments, AAT is preferentially optimized by the correct set of post-translational modifications, obtained by expression and isolation as an endogenous protein, or by expression in a suitable recombinant system.
[0032] In some embodiments, AAT is extracted from human plasma. In some embodiments, AAT is extracted from pooled human plasma using an AAT-enriched plasma preparation.
[0033] Mesenchymal stem cells (MSCs) interact with most cell types of the innate and adaptive immune systems, including B cells, T cells, dendritic cells (DCs), natural killer (NK) cells, neutrophils, and macrophages, mitigating the response to pathogens. MSCs also play a role in controlling tissue inflammation. The therapeutic effects of MSCs are largely due to the secretion of immunomodulatory and regenerative factors, some of which may be mediated via host phagocytic cells that remove administered MSCs and adapt in the process to immunomodulatory and regenerative support functions. Given that extracellular vesicles of MSCs can mediate these functions, vesicles can be obtained from, isolated from, and administered to MSCs, either expressed from AAT-gene-modified cells themselves or combined with isolated MSCs to which AAT has been added (enriched).
[0034] In a preferred embodiment, recombinant AAT expressed from mesenchymal stem cells has beneficial effects including immunomodulatory function, homing to lung tissue, reduction of cytokine storms, prevention of SARS-CoV-2 entry into host cells, and / or prevention of damage to lung tissue.
[0035] It was unexpected that the pharmaceutical compositions described herein, which are concentrated with AAT, preferably with isolated recombinant AAT protein, could be used as agents in the treatment and / or prevention of viral infections.
[0036] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of viral infection, wherein the extracellular vesicles are exosomes and / or microvesicles.
[0037] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of viral infection, wherein the extracellular vesicle comprises an AAT protein, preferably an AAT protein expressed from a modified MSC, and one or more biological factors selected from the group consisting of cytokines such as IFN-γ, IL-8, IL-10, and TGF-β, HLA-G, cholesterol, ceramide, phosphoglycerides, saturated fatty acid acyl chains, prostaglandins, and nucleic acids such as RNA, preferably miRNA, siRNA, and shRNA.
[0038] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of viral infection, wherein the extracellular vesicles have an average diameter of 1 to 500 nm, preferably about 10 to 200 nm, and more preferably 20 to 150 nm.
[0039] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of viral infection, wherein the concentration of extracellular vesicles is 0.01 to 100 mg / ml, preferably 0.1 to 10 mg / ml, and more preferably 1 to 5 mg / ml.
[0040] Exosomes are extracellular vesicles with a membrane structure of 1–500 nm, preferably about 10–200 nm, more preferably 20–150 nm. Exosomes contain cytokines such as IFN-γ, IL-8, IL-10, and TGF-β, HLA-G, cholesterol, ceramides, phosphoglycerides, saturated fatty acid acyl chains, prostaglandins, and nucleic acids such as RNA, preferably miRNA, siRNA, and shRNA. Physiologically, exosomes assist in the intercellular transport of proteins and RNA. Immunologically, exosomes can exhibit antigen-presenting capabilities. Similarly, exosomes have been found to be involved in the pathophysiology of cardiovascular, renal, neurological, and ocular diseases. Furthermore, exosomes may play a significant role in cancer metastasis. It is surprising that exosomes isolated from MSCs can be used as agents for the treatment and / or prevention of viral infections without exhibiting undesirable side effects regarding pathophysiological effects.
[0041] In some embodiments, the present invention relates to a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of viral infection, wherein the extracellular vesicle is an exosome and can be obtained by a method comprising the following steps: a) A step of providing a cell culture supernatant containing exosomes derived from mesenchymal stem cells (MSCs), which are optionally genetically modified to express exogenous alpha-1 antitrypsin (AAT); and b) A step of isolating the exosomes by removing cells and / or cell debris, preferably by centrifugation, high-performance liquid chromatography (HPLC), and / or ultrafiltration.
[0042] In some embodiments, exosomes can be obtained by a method that further includes determining the protein concentration of isolated exosomes by removing cells and / or cell debris, preferably by centrifugation, high-performance liquid chromatography (HPLC), and / or ultrafiltration.
[0043] Because exosomes in biological samples are extremely small and rare, they are preferably isolated by removing cells and / or cell debris using centrifugation, high-performance liquid chromatography (HPLC), and / or ultrafiltration, employing techniques established in the art. These isolation methods are preferably achieved by sucrose density gradient ultracentrifugation, preferably by efficient immunoaffinity and / or microfluidic systems approaches.
[0044] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of viral infections, wherein the mesenchymal stem cells (MSCs) are selected from human, mouse, and rat mesenchymal stem cells.
[0045] In some embodiments, the present invention relates to the pharmaceutical compositions described herein for use as agents in the treatment and / or prevention of viral infections, wherein the MSCs are selected from human MSCs derived from induced pluripotent stem cells (iPSCs), umbilical cord blood, umbilical cord tissue, placenta, bone marrow, bone or adipose tissue, and platelet lysates.
[0046] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of a viral infection, the composition being administered topically and / or locally to the mucous membrane surface of the target respiratory tract and / or oral cavity.
[0047] It was surprising that the pharmaceutical compositions described herein could be administered topically and / or locally to the mucosal surface of the target airways and / or lumens. The advantage of this is that the drug can be applied directly to the skin. Compared to systemic drugs, side effects and toxicity to other organs are reduced. It was also surprising that topical or localized administration did not result in significant degradation of AAT and / or vesicles. Both the formulation containing the combination of AAT and extracellular vesicles before administration and the composition after administration appear to be sufficiently stable to achieve therapeutic and / or prophylactic effects.
[0048] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of viral infections, the composition being suitable for administration to the upper or lower respiratory tract, lungs, nasal cavity, oral cavity and / or throat of the target.
[0049] This results in local efficacy within the respiratory tract, including the upper or lower respiratory tract, lungs, nasal cavity, oral cavity, and / or throat. The delivered drug acts with maximum lung specificity, combining rapid onset of action with a long duration of effectiveness, thus minimizing undesirable systemic effects.
[0050] In some embodiments, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of viral infections, the composition being in liquid or powder form and suitable for spraying and / or inhalation into the nasal cavity and / or oral cavity of a target.
[0051] Powdered compositions have the advantage of high stability and do not require any preservatives that are necessary in liquid formulations. Compositions in liquid or suspension form are advantageous because they offer high local drug (active substance / in this case vesicles and / or AAT) concentrations, rapid onset of drug action, excellent respiratory selectivity, reduced systemic drug exposure, and reduced side effects.
[0052] In some embodiments, the composition may be in the form of an aerosol, which is either a solution containing the active agent, a suspension of solid drug particles in a gas, or a dry powder. Aerosols have three advantages: small particle size, low spray velocity, and low temperature. These factors may reduce upper airway embedding and increase airway deposition of particles, particularly in the narrower airways, compared to the same drug administered from a chlorofluorocarbon-driven pressurized metered-dose inhaler.
[0053] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment of a viral infection, the composition being administered by introducing a therapeutically effective amount of the composition into the bloodstream, eyes, nasal cavity, oral cavity, throat and / or lungs.
[0054] In another embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment of a viral infection, the composition being administered by intravenous injection, subcutaneous injection, intraperitoneal injection and / or inhalation (preferably by inhalation).
[0055] In some embodiments, the present invention relates to the pharmaceutical compositions described herein for use as agents in the treatment of medical conditions further related to cardiovascular diseases, kidney injuries, immune disorders, tumors, and neurological disorders.
[0056] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of a viral infection, wherein the subject is suspected of having a viral infection and / or has been in close proximity to and / or in contact with a person who has a viral infection.
[0057] The pharmaceutical compositions described herein are intended for prophylactic use (or risk reduction use) to prevent (or reduce the risk of) the development of disease caused by viral infection in subjects exhibiting symptoms of viral infection and / or subjects in close proximity to and / or in contact with individuals with viral infections. Furthermore, the pharmaceutical compositions described herein have been proposed for the first time to be used as pharmaceuticals for the treatment of viral infections.
[0058] In some embodiments, the present invention relates to the pharmaceutical compositions described herein for use as agents in the treatment of medical conditions involving fever, cough, fatigue, inflammation, limb pain, sore throat, itchy throat, diarrhea, conjunctivitis, headache, loss of taste or smell, discoloration of hands and feet, skin rash, difficulty breathing, shortness of breath, chest pain or pressure, and / or loss of speech or motor skills. In some embodiments, such symptoms are present in patients who have or are at risk of a viral infection.
[0059] In some embodiments, the present invention relates to the pharmaceutical compositions described herein for use as pharmaceuticals in the treatment of pneumonia, viral sepsis, acute respiratory distress, renal failure, and other medical conditions further related to cytokine release.
[0060] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment of a medical condition, said medical condition resulting from a viral infection, preferably an infection by an enveloped positive-strand RNA virus.
[0061] In one preferred embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment and / or prevention of a viral infection, wherein the virus is derived from the Coronaviridae family, preferably betacoronavirus, more preferably SARS-CoV.
[0062] In a more preferred embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment and / or prevention (preferably prevention) of a viral infection, wherein the virus is SARS-CoV-2. In a preferred embodiment, the present invention relates to the treatment and / or prevention of SARS-CoV-2 infection by topical and / or localized administration to the oral cavity and / or respiratory tract of subjects at risk of or in such a condition of SARS-CoV-2 infection.
[0063] The three deadly zoonotic coronaviruses, MERS-CoV, SARS-CoV, and SARS-CoV-2, are all thought to induce an excessive and abnormal host immune response, leading to severe lung lesions and acute respiratory distress syndrome. SARS-CoV-2 enters host cells via angiotensin-converting enzyme 2 (ACE2) on the cell surface. A related cytokine storm may be involved in the pathogenesis. In COVID-19 patients, pro-inflammatory cytokines and chemokines, including tumor necrosis factor (TNF)α, interleukin 1β (IL-1β), IL-6, granulocyte colony-stimulating factor, interferon-gamma-inducible protein-10, monocyte chemoattractant protein-1, and macrophage inflammatory protein 1-α, were significantly elevated.
[0064] It is remarkable that the compositions described herein achieve the effect of therapeutic interventions that can reduce excessive inflammation, thereby preventing peripheral organ damage and long-term functional impairment in people who have survived serious illnesses, while simultaneously enabling an effective immune response against pathogens.
[0065] In another embodiment, the present invention relates to a pharmaceutical composition for use as described herein, which prevents infection by a virus, preferably SARS-CoV, more preferably SARS-CoV-2.
[0066] The transmembrane serine protease TMPRSS2 is essential for S protein priming of MERS, SARS-CoV, and SARS-CoV2 coronaviruses, a process necessary for the virus to enter host cells. Therefore, inhibition of TMPRSS2 is a promising approach to prevent coronavirus infection. It is surprising that alpha-1 antitrypsin is an inhibitor of the SARS-CoV2 priming protease TMPRSS2.
[0067] In another embodiment, the present invention relates to a pharmaceutical composition described herein for use as a pharmacopoeia in combination with existing treatments, or as a pre-treatment for viral infections, preferably SARS-CoV-2 infection.
[0068] In a further embodiment, the present invention relates to a delivery system for delivering a pharmaceutical composition described herein for use as a pharmacopoeia in the treatment and / or prevention of a viral infection, the delivery system comprising: a) a pharmaceutical composition according to any one of the claims, comprising one or more pharmaceutical excipients; and b) a dispenser.
[0069] In one preferred embodiment, the present invention relates to a delivery system for delivering a pharmaceutical composition described herein for use as a pharmaceutical in the treatment and / or prevention of a viral infection, wherein the composition is in liquid or powder form, and the dispenser is suitable for spraying the composition into the nasal cavity and / or oral cavity of a target, and / or for inhalation of the composition.
[0070] In one embodiment, the composition is formulated to allow cryopreservation without significantly impairing the function of isolated extracellular vesicles.
[0071] In one embodiment of the present invention, the composition comprises a liquid formulation. Liquid formulations currently dominate the nasal spray market because they are considered particularly convenient for topical applications that prevent dryness and scabbing associated with chronic nasal diseases by humidifying the nasal passages. A variety of liquid formulation devices are commercially available on the market, including Ferring's Rhinyle catheter and GlaxoSmithKline unit-dose pipettes.
[0072] In another embodiment of the present invention, the composition comprises a powder formulation. Powder formulations can offer advantages such as high stability and the possibility of avoiding the use of preservatives used in liquid compositions. Powders tend to adhere to the moist surface of the nasal mucosa before being dissolved and removed. Various powder drying devices are available on the market, including AstraZeneca's Turbohaler, GlaxoSmithKline's Diskus / Accuhaler, Almirall's Genuair, and Norton Healthcare's Airmax.
[0073] In one embodiment of the present invention, the composition comprises a suspension formulation. The inhalation solution and suspension formulation are typically aqueous formulations containing therapeutically effective components, and may also contain additional excipients. The advantages of the suspension formulation are the same as those of the liquid formulation.
[0074] In another embodiment of the present invention, the composition comprises an aerosol. The aerosol is a suspension of liquid and / or solid particles produced by an aerosol generator such as a small volume nebulizer (SVN), a pressurized metered-dose inhaler (pMDI), or a dry powder inhaler (DPI). Aerosol deposition is the process by which aerosol particles are deposited on an absorbent surface.
[0075] The main mechanisms of aerosol deposition include, but are not limited to, inertial impaction, gravitational sedimentation (sedimentation), and diffusion. Inertial impaction occurs with larger (>3 μm) fast-moving particles. Gravitational sedimentation is a function of particle mass and time, and the sedimentation velocity is proportional to the particle size and mass. Diffusion occurs with particles smaller than 1 μm. These mechanisms are at work when aerosol particles are inhaled orally or nasally. Larger particles (>10 μm) usually reach the oropharynx primarily by inertial impaction; generally, particles between 5 and 10 μm reach the proximal stage of the lower respiratory tract, and particles between 1 and 5 μm reach the periphery of the lungs.
[0076] Particle size, along with particle velocity and sedimentation time, plays a crucial role in lung deposition. When particle size exceeds 3 μm, aerosol deposition moves from the periphery of the lungs to the conductive airways. When particle size exceeds 6 μm, deposition in the oral cavity and pharynx increases. Exhalation loss is significant for very small particles smaller than 1 μm. Therefore, particle sizes of 1–5 μm are sometimes preferable for reaching the periphery of the lungs, while 5–10 μm particles mainly deposit in the conductive airways, and 10–100 μm particles mainly deposit in the nose.
[0077] In embodiments of the present invention, the above-described aerosol agent is intended for the formulation and distribution of the composition of the present invention, thereby targeting a specific portion of the airway or combining aerosols of different sizes to distribute the activator throughout various areas of the oral cavity and / or airway.
[0078] The advantages of aerosolized drugs include: 1) aerosol doses are generally smaller than systemic doses; 2) the onset of action of inhaled drugs is usually faster than with conventional oral administration; 3) the drug is delivered directly to the lungs, minimizing systemic exposure; 4) compared to systemic administration, inhalation results in lower frequency and severity of systemic side effects; and 5) inhaled drug therapy is less painful and relatively more comfortable than injection. Currently available aerosol formulations and corresponding inhalation devices include, for example, AccuNeb®, Xopenex®, and ProAir HFA®.
[0079] These compositions can be prepared using the compositions of the present invention to be suitable for nasal and / or oral spraying and / or inhalation.
[0080] In a preferred embodiment, the dispenser is used to convert the pharmaceutical composition into a liquid, powder, suspension, or aerosol and is suitable for inhalation and / or spraying so that the drug particles reach the airways, lungs, other areas of the respiratory tract, and / or the oral cavity and / or nasal cavity directly. The dispenser is preferably selected from the group of small-volume nebulizers, pressurized metered-dose inhalers, metered-dose inhaler attachments, dry powder inhalers, nasal sprays, and oral sprays.
[0081] In one embodiment of the present invention, the dispenser is a small-volume nebulizer. Its advantages are: 1) it can aerosolize any drug solution; 2) it can aerosolize drug mixtures (>1 drug) if the drugs are compatible; 3) it requires minimal patient cooperation or adjustment; 4) it is useful for very young patients, very elderly patients, debilitated patients, or patients in pain; 5) it allows for changes in drug concentration and dosage; 6) different types, brands, and models have different performance characteristics; and 7) it can be used with a normal breathing pattern and does not require pause in inspiration to achieve the desired effect.
[0082] In one embodiment of the present invention, the dispenser is a pressurized metered-dose inhaler. Its advantages are that the dispenser is portable, lightweight, and compact, offers the convenience of multiple doses, has a short treatment time, provides reproducible release doses, requires no drug preparation, and the formulation is less susceptible to contamination.
[0083] In another aspect of the present invention, the dispenser is an accessory for a metered-dose inhaler. Its advantages include reduced retention and loss of the drug in the oral cavity and pharynx, a 2-4 times increase in inhaled drug compared to a pMDI (pressurized metered-dose inhaler, or puffer) alone, the ability to use the pMDI during acute airflow obstruction accompanied by respiratory distress, no drug preparation required, simplified operation and adjustment of the pMDI, and help reduce local and systemic side effects.
[0084] In one embodiment of the present invention, the dispenser is a dry powder inhaler. Its advantages are that it is small and portable, has a built-in dosage, does not require a propellant, operates by breathing, and has a short preparation and administration time.
[0085] In one further embodiment, the present invention relates to a combination of pharmaceuticals. The characteristics of the compositions described herein may be used to illustrate the combination.
[0086] In one preferred embodiment, the present invention relates to a combination of pharmaceuticals and includes the following: (a.) A therapeutically effective amount of extracellular vesicles derived from MSCs, preferably exosomes, and (b) A therapeutically effective dose of AAT.
[0087] The present invention relates to a combination for use in the treatment of viral infections such as coronavirus infection, and / or for the treatment and / or prevention of SARS coronavirus-related respiratory disease, and for corresponding therapeutic methods. The present invention also relates to the combined administration of a therapeutically effective amount of extracellular vesicles derived from MSCs, preferably exosomes, and a therapeutically effective amount of AAT in such therapies.
[0088] Therefore, the compositions of the present invention relate to advantageous combinations not previously described, preferably combinations characterized by a synergistic effect between two active agents.
[0089] Those skilled in the art would not have anticipated that these two drugs, effective against viral infection or disease, would interact beyond a cumulative effect. Even if the reduction in viral replication and / or infection achieved by extracellular vesicles and AAT when each is administered alone is known to those skilled in the art, the synergistic effect could not have been predicted based on the expectations of those skilled in the art. Typically, targeting two mechanisms with antiviral effects does not usually result in a synergistic effect, nor does it produce an additional effect or a negligible additive effect. Not bound by theory, targeting two targets with antiviral or related effects usually does not yield further quantitative effects because viral infection is already inhibited, so a second (combined) factor generally does not produce an additional effect, or at best a small cumulative effect. Therefore, by targeting a different position of the same or related antiviral effect with the second drug, no additional effect is expected, and only the effect already achieved by the first drug is enhanced. Contrary to expectations, a surprising quantitative synergistic effect was achieved by extracellular vesicles and AAT.
[0090] In some embodiments, the extracellular vesicles and AAT have a relative amount of 10,000:1 to 1:10,000 by weight, preferably 10:1 to 1:10 by weight, and more preferably about 5:1 to 1:5 by weight.
[0091] Embodiments and features of the present invention are described with respect to compositions comprising extracellular vesicles from MSCs and AAT for the treatment and / or prevention of viral infections, and delivery systems are deemed to be disclosed in relation to all other aspects of the present disclosure, such that compositions can be characterized using features that characterize compositions, combinations, or delivery systems, and vice versa. Various aspects of the present invention are integrated, benefit from, build upon, and / or relate to the common and remarkable discovery of pharmaceutical compositions comprising extracellular vesicles isolated from mesenchymal stem cells (MSCs) and alpha-1 antitrypsin (AAT) protein for use as pharmaceuticals in the treatment and / or prevention of viral infections in human subjects.
[0092] In one further embodiment, the present invention relates to a pharmaceutical composition comprising the alpha-1 antitrypsin (AAT) protein for use as a pharmacopoeia in the treatment and / or prevention of viral infections in human subjects, the composition being administered in aerosol form and / or via other forms suitable for administration by spraying and / or inhalation.
[0093] In this embodiment, in some embodiments, the composition is preferably free from extracellular vesicles, such as MSC-derived exosomes. However, the remaining disclosures provided herein are still relevant to this embodiment of the invention, for example, with respect to dosage forms, apparatus, medical procedures, and other features of the invention.
[0094] For example, in some embodiments, the AAT-containing composition may be in the form of a solution containing AAT protein, such as a suspension of solid drug particles in a gas, or a dry powder such as a micronized powder.
[0095] In some embodiments, the composition is either a solution containing an activator, a suspension of solid drug particles in a gas, or a dry powder that is aerosolized at the time of administration, i.e., using a suitable administration device, or administered to the patient in an aerosol. Aerosols have advantages associated with AAT administration, namely, their smaller particle size, which may reduce impaction in the upper airways and increase particle accumulation, particularly in the narrower airways, compared to the same drug administered with a chlorofluorocarbon-driven pressurized metered-dose inhaler. Nevertheless, in some embodiments, a chlorofluorocarbon-driven pressurized metered-dose inhaler is suitable and can be used for administering AATs.
[0096] In one embodiment, the present invention relates to a pharmaceutical composition described herein for use as an agent in the treatment and / or prevention of viral infections, wherein the composition is administered by introducing a therapeutically effective amount of the composition into the nasal cavity, oral cavity, and respiratory tract such as the throat and / or lungs, preferably by inhalation and / or spraying, the composition being prepared, preferably using appropriate apparatus, and including an AAT protein, an example of which is provided below. Essentially, any form of administration suitable for aerial delivery of the AAT protein to the nasal cavity, oral cavity, and / or respiratory tract is intended. Such a form of administration results in a remarkable reduction in infection, preferably prevention of infection, or prevention or reduction of infection that leads to a severe viral disease response. The AAT protein delivered to the nose, oral cavity, or respiratory tract can actively prevent or mitigate viral particle infection, such as SARS-CoV-2 infection, in target host cells.
[0097] In some embodiments, the AAT solution is provided for administration exhibiting concentrations of approximately 1 to 1000 mg of protein per 100 mL of solution, preferably 10 to 500 mg of protein per 100 mL of solution, and more preferably 50 to 200 mg or approximately 100 mg of protein per 100 mL of solution. Such solutions are suitable for aerosolization at the time of administration using appropriate equipment, or for generating particles or droplets at the time of administration, thereby enabling inhalation or spraying into the oral cavity or nasal cavity and / or upper respiratory tract or lungs.
[0098] All cited patent and non-patent documents are incorporated herein by reference in their entirety.
[0099] Mesenchymal stem cells:
[0100] As used herein, “mesenchymal stem cells” (also known as “mesenchymal cells” or “MSCs” in some embodiments, and also as mesenchymal stromal cells) are pluripotent cells that can differentiate into connective tissue, bone, cartilage, and circulatory and lymphatic cells. Mesenchymal stem cells are found in the mesenchyme, which is part of the embryonic mesoderm consisting of loosely packed, spindle-shaped or star-shaped, unspecialized cells. Mesenchymal stem cells as used herein include, but are not limited to, CD34-negative stem cells.
[0101] In one embodiment of the present invention, mesenchymal cells are fibroblast-like plastic-adhering cells, defined in some embodiments as pluripotent mesenchymal stromal cells, and also include CD34-negative cells. To avoid any doubt, the term mesenchymal stem cells encompass pluripotent mesenchymal stromal cells, which also include subpopulations of mesenchymal cells, MSCs, and their precursors, which consist of pluripotent or pluripotent self-regenerating cells that can differentiate into multiple cell types in vivo.
[0102] As used herein, CD34-negative cells mean cells that lack CD34 or cells that express negligible levels of CD34 on their surface. CD34-negative cells and methods for isolating such cells are described, for example, in Lange C. et al., "Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine". J. Cell Physiol. 2007, Apr. 25.
[0103] Mesenchymal cells can be distinguished from hematopoietic stem cells (HSCs) by many indicators. For example, HSCs are known to float in culture and not adhere to plastic surfaces. In contrast, mesenchymal cells adhere to plastic surfaces. The CD34-negative mesenchymal cells of the present invention are adhesive in culture.
[0104] MSCs can be cultured using known protocols. For example, human MSCs derived from induced pluripotent stem cells (iPSCs), umbilical cord blood, umbilical cord tissue, placenta, bone marrow, bone or adipose tissue, and other MSCs can be cultured as adherent cells on plastic surfaces in the presence of platelet lysates. As used herein, “platelet lysates” is an alternative supplement to fetal bovine serum (FBS) in experimental and clinical cell cultures. It is obtained from human platelets after a freeze / thaw cycle. The freeze / thaw cycle lyses platelets, releasing large amounts of growth factors necessary for cell proliferation. FBS-free cell culture media, such as those free of platelet lysates or chemically defined animal components, are used in cell therapy and regenerative medicine. These are generally marketed in GMP (Good Manufacturing Practice) quality, which is the standard for regulatory approval. Pooled human platelet lysates are used as culture supplements to promote MSC proliferation. Alternative MSC culture procedures are also available and known to those skilled in the art.
[0105] Genetically modified MSCs:
[0106] MSCs can be genetically modified to express, for example, a transgenic AAT using techniques known in the art. In some embodiments, the nucleic acid encoding AAT is introduced into an MSC, preferably stably incorporated into or maintained within the cell, and subsequently expressed from the modified MSC.
[0107] As used herein, “genetic modification,” also known as genetic engineering or genetic recombination, is the technique of altering the properties of plants, animals, or microorganisms by isolating and replicating desired genetic material using recombinant DNA methods, or by artificially synthesizing DNA and transplanting DNA fragments obtained in another organism. This is done by inserting them into other organisms. This technique is used, for example, in the development of mammalian cells, fungi, and bacteria that produce pharmaceuticals. There are various genetic modification methods: microbial vectors, microprojectile bombardment, electroporation, microinjection, transponses / transponsable elements, cloning, transfection, retroviral vectors, knock-in and knock-out techniques, marker-assisted selection, etc.
[0108] Suitable technologies for modifying MSCs include, but are not limited to, the use of viral vectors such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and non-viral vectors (liposomes and plasmids), or gene editing such as CRISPR / Cas9, ZFN, and / or TALEN. Viral vectors are the most commonly used tool in MSC genetic modification protocols, and the high efficiency of viral transduction in these cells has been demonstrated to not affect immunophenotypic characteristics, as well as the potential for conserved cell differentiation and secretion of bioactive molecules after recombination. Furthermore, viral transduction ensures stable and long-term transcription of the gene of interest, resulting in higher efficiency compared to other methods of MSC genetic modification that do not use viral vectors. Site-specific gene insertion can be achieved using tools such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENS), or clustered, regularly spaced short palindromic repeats (CRISPR / Cas9), which are nucleases capable of recognizing and directly inserting genes in a site-specific manner. These molecular editing tools are highly efficient and precise and can be used to improve the safety and efficiency of gene insertion / expression.
[0109] Any given gene delivery method is included in the present invention, and preferably the present invention relates to viral vectors or non-viral vectors, and to biological or chemical methods of transfection. This method enables stable or transient gene expression in the system used.
[0110] Genetically modified viruses are widely used for gene delivery to stem cells. The preferred viral vectors for genetic modification of MSCs described herein are retroviral vectors, particularly gamma retroviral vectors. Gamma retroviruses (sometimes called mammalian type C retroviruses) are sister genera of the lentivirus phylogenetic group and members of the orthoretrovirinae subfamily of the retroviridae family. Mouse leukemia virus (MLV or MuLV), feline leukemia virus (FeLV), heterotropic mouse leukemia virus-associated virus (XMRV), and gibbon leukemia virus (GALV) are members of the gamma retrovirus genus. Those skilled in the art are familiar with the techniques required for the use of gamma retroviruses in genetic modification of MSCs. For example, vectors described by Maetzig et al. (Gamma retroviralvectors: biology, technology and application, 2001, Viruses Jun;3(6):677-713) or similar vectors can be used. For example, mouse leukemia virus (MLV), a simple gamma retrovirus, can be transformed into an efficient medium for gene therapy in the context of creating gamma retrovirus-modified mesenchymal stem cells (MSCs) and then expressing therapeutic transgenes from these MSCs after delivery to the target.
[0111] RNA viruses such as adenoviruses or lentiviruses, or other retroviruses may be used. Adenoviruses have been used to generate a series of vectors for gene transfer cell engineering. The first generation of adenovirus vectors was produced by deleting the E1 gene (necessary for viral replication) to generate a vector with a cloning capacity of 4 kb. Further deletion of E3 (responsible for the host immune response) enabled a cloning capacity of 8 kb. Further generations including E2 and / or E4 deletions have been generated. Lentiviruses are members of the retroviridae family of viruses (M. Scherr et al., Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr Gene Ther. 2002 Feb; 2(1):45-55). Lentiviral vectors are produced by deleting the entire viral sequence except for the LTR and cis-action packaging signal. The resulting vector has a cloning capacity of approximately 8 kb. One of the features that distinguishes these vectors from retroviral vectors is their ability to transduce dividing cells, non-dividing cells, and even terminally differentiated cells.
[0112] Nonviral methods can also be used, including alternative strategies such as the application of conventional plasmid delivery or targeted gene integration using integrase or transposase techniques. These represent vector transformation approaches, which have the advantages of being efficient and often site-specific in their integration. Physical methods for introducing vectors into cells are known to those skilled in the art. One example relates to electroporation, which involves the use of short, high-voltage electrical pulses to create transient pores in the membrane by overcoming capacitance. One advantage of this method is that it can be used for both stable and transient gene expression in most cell types. Another method relates to the use of liposomes or protein delivery domains. Suitable methods are known to those skilled in the art and do not limit the embodiments of the present invention.
[0113] In one embodiment, the exogenous AAT expressed from the transgenic AAT gene as a product of genetic modification of MSCs is controlled by a constitutive promoter, or an inductive promoter or a conditional promoter, preferably a constitutive promoter.
[0114] As used herein, a constitutive promoter is an inherently unregulated promoter that enables continuous transcription of the gene in question. Constitutive promoters are preferred because they enable highly consistent expression of AAT, thereby enriching the exosome protein used in the present invention. In one embodiment, the genetically modified mesenchymal stem cells described herein are characterized in that the AAT expression promoter is an EF1α promoter, such as the EF1αS promoter, PGK promoter, CMV or SV40 virus promoter, GAG promoter, or UB promoter.
[0115] As used herein, “nucleic acid” means any nucleic acid molecule, including but not limited to DNA, RNA, and their hybrids or modified variants. “Exogenous nucleic acid” or “exogenous genetic element” is any nucleic acid introduced into a cell that is not a component of the cell’s “original” or “natural” genome. Exogenous nucleic acid may be incorporated or not, or may be associated with a stably transfected nucleic acid. The exogenous nucleic acid preferably encodes AAT, thereby resulting in the expression of the exogenous AAT protein.
[0116] Exogenous protein:
[0117] As used herein, “exogenous protein” refers to a protein expressed from a non-natural genetic element of a cell. For example, the coding nucleic acid that encodes an exogenous protein is not present in naturally occurring cells. For example, an exogenous protein is expressed through exogenous DNA that is integrated into the genome of the expressing cell. Thus, the term exogenous AAT refers to an AAT protein that is expressed from an exogenous AAT nucleic acid or that is recombinantly produced and isolated for later use, rather than being expressed from an existing (natural; endogenous) AAT gene. In some embodiments, an AAT protein is expressed from a naturally occurring coding sequence but is considered exogenous if it is under the control of a modified / transgenic promoter or other genetic regulator.
[0118] As used herein, “recombinant protein” is a protein encoded by a recombinant gene and produced by a specific recombinant expression system. Recombinant proteins are important tools for studying biological processes and for the industrial production of protein-based pharmaceuticals. The selection of an appropriate expression system depends on the properties of the recombinant protein and its intended use, and is essential for producing sufficient quantities of the protein. Commonly used expression systems include Escherichia coli, Pichia pastris, baculovirus, insect cells, and mammalian cells.
[0119] Extracellular vesicles:
[0120] As used herein, “extracellular vesicles” (EVs) are particles separated by a lipid bilayer. They are spontaneously released from cells, and unlike cells, they cannot replicate. Their diameters range from nearly the size of the smallest physically possible monolayer liposome (typically around 20-30 nanometers) to over 10 microns, although most extracellular vesicles are less than 200 nm in size. They carry cargo of parental cell-derived proteins, nucleic acids, lipids, metabolites, and even organelles. Most cells studied to date, including some bacteria, fungi, and plant cells enclosed by cell walls, are thought to release extracellular vesicles. A wide variety of subtypes of extracellular vesicles have been proposed, defined in various ways by size, biosynthetic pathway, cargo, cell source, and function, resulting in a historically heterogeneous nomenclature that includes terms such as exosomes and ectosomes.
[0121] As used herein, “microvesicles,” also known as ectosomes or microparticles, are a type of extracellular vesicle released from the cell membrane. In multicellular organisms, microvesicles and other EVs are found in both tissues (intercellular spaces) and many types of body fluids. Separated by a phospholipid bilayer, microvesicles can range in size from as small as the smallest EV (30 nm in diameter) to as large as 1000 nm. They are thought to be, on average, larger than intracellularly produced EVs known as exosomes. Microvesicles play a role in intercellular communication, transporting molecules such as mRNA, miRNA, and proteins between cells.
[0122] As used herein, “exosomes” are extracellular vesicles secreted by most eukaryotic cells and are involved in intercellular communication. The components of exosomes include proteins, DNA, mRNA, microRNA, long non-coding RNA, and circular RNA. These are a subset of extracellular vesicles surrounded by a lipid bilayer membrane, secreted by most eukaryotic cells, and have a diameter size of 1 to 500 nm, preferably between about 10 to 200 nm, and more preferably between 20 to 150 nm.
[0123] As used herein, references to “extracellular vesicles” may be replaced with “exosomes,” and vice versa.
[0124] As used herein, "concentration" refers to the amount of a component divided by the total volume of a mixture. Concentration can represent any type of chemical mixture, but most often it includes the solute and solvent in a solution. Molar concentration has variations, such as standard concentration and osmotic concentration. Types of concentration include mass concentration, molar concentration, number concentration, and volume concentration.
[0125] The concentrations of extracellular vesicles or microvesicles and exosomes are determined by conventional methods, such as using a Nanosight, an optical microscope suited for quantifying small particles, or an ExoELISA, an ELISA kit specifically designed for quantifying exosome particles, to lyse exosomes, then quantify standard proteins, measure particle size with an electron microscope, and distinguish exosomes from other vesicles.
[0126] Extracellular vesicles (EVs) have recently attracted significant attention due to their potential relevance to diagnosis and treatment. Various techniques are used for the isolation and analysis of EVs. Size exclusion chromatography (SEC), which separates subjects by size, is widely applied for purification and analysis. Other methods are used for vesicle isolation, including ultracentrifugation, size exclusion (filtration or chromatography), immunoaffinity isolation, precipitation (ExoQuick or "salting out"), or combinations of the above techniques. Techniques such as HPLC and / or ultrafiltration can also be used to generate extracellular vesicles such as exosomes.
[0127] As used herein, “high-performance liquid chromatography (HPLC)” (formerly known as high-pressure liquid chromatography) is an analytical chemistry technique used to separate, identify, and quantify individual components in a mixture. It involves a pump for passing a pressurized liquid solvent containing a sample mixture through a column packed with a solid adsorbent. Each component in the sample interacts with the adsorbent in a slightly different way, generating different flow rates for each component, and separating the components as they leach out of the column. HPLC, such as size exclusion HPLC, can be used to characterize and isolate extracellular vesicles, such as exosomes.
[0128] It has been previously shown that exosomes secreted from adipose-derived mesenchymal stem cells can be obtained using three common techniques: stepwise ultracentrifugation at 100,000 g, ultrafiltration with a 3 kDa exclusion membrane, and charge-based precipitation. Therefore, exosomes generated by mesenchymal stem cells can be obtained in high quality for in vitro or in vivo experiments by ultrafiltration and ultracentrifugation. For subsequent therapeutic applications, ultrafiltration is preferred over exosomes obtained by ultracentrifugation because they have a higher concentration and no extracellular vesicle aggregation.
[0129] As used herein, "ultrafiltration" is a type of membrane filtration that uses forces such as pressure or concentration gradients to pass a semipermeable membrane through which separation occurs. Suspended solids and high molecular weight solutes are retained in the retention solution, while water and low molecular weight solutes pass through the membrane to the permeate. This separation process is used in industry and research for the purification and concentration of high molecular weight solutions, particularly protein solutions, extracellular vesicles, microvesicles, and exosomes.
[0130] Alpha-1 antitrypsin (AAT):
[0131] Alpha-1 antitrypsin (also known as A1AT, AAT, PI, or SERPINA1) is a glycoprotein of approximately 52 kDa that is one of the most abundant endogenous serine protease inhibitors (SERPIN superfamily). AAT is considered an acute-phase protein, and its levels can increase several-fold during acute inflammation.
[0132] The AAT coding region is preferably any nucleic acid that exhibits AAT function that is reduced, the same, similar, or increased compared to human AAT, or is functionally similar to human AAT, and codes for a naturally occurring or synthetic AAT protein sequence. The amino acid sequence of AAT is available from the NCBI database under accession number 1313184B. The corresponding nucleic acid sequence coding for AAT may be provided by those skilled in the art of molecular biology or genetics. The use of AAT sequence variants exhibiting functional similarity or similarity to unmodified human AAT is included in the present invention.
[0133] The SERPINA1 coding sequence (CDS) published at http: / / www.ncbi.nlm.nih.gov / nuccore / NM_000295.4 is one preferred embodiment and includes bases 262 to 1518 of the complete sequence (SEQ ID NO: 1):
[0134] In some embodiments of the present invention, the CDS is optimized for codons to increase protein production. The coding sequence after codon optimization is preferably as follows (SEQ ID NO: 2):
[0135] The nucleotide sequences described in SEQ ID NO: 1 and / or 2 encode the human AAT protein shown in SEQ ID NO: 3 and are preferred in the present invention: MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALV NYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLP KLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
[0136] Therefore, the present invention encompasses the use of genetically modified MSCs expressing the transgenic AAT described herein, comprising nucleic acid molecules selected from the group consisting of: a) For example, a nucleic acid molecule containing a nucleotide sequence encoding the AAT protein shown in SEQ ID NO: 3, preferably a nucleic acid molecule containing a nucleotide sequence shown in SEQ ID NO: 1 or 2, b) A nucleic acid molecule complementary to the nucleotide sequence shown in a); c) A nucleic acid molecule comprising a nucleotide sequence having sufficient sequence identity to be functionally similar / equivalent to the nucleotide sequence described in a) or b), preferably having at least 70%, 80%, preferably 90%, and more preferably 95% sequence identity with the nucleotide sequence shown in a) or b); d) Nucleic acid molecules that, as a result of the genetic code, are degenerated into the nucleotide sequences shown in a) to c); and / or e) A nucleic acid molecule represented by the nucleotide sequences a) to d) that has been modified by deletion, addition, substitution, translocation, inversion and / or insertion, and is functionally similar / equivalent to the nucleotide sequences a) to d).
[0137] Therefore, the present invention encompasses the use of genetically modified MSCs as described herein, comprising the AAT protein shown in SEQ ID NO: 3 or a variant thereof, or a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 3.
[0138] The present invention includes further sequence variants of the sequence shown in SEQ ID NO: 3, particularly sequence variants having at least 70% sequence identity to SEQ ID NO: 3, preferably at least 80%, 85%, 90%, or at least 95% sequence identity to SEQ ID NO: 3. Such sequence variants are preferably functionally similar to or equivalent to human AA disclosed herein. Changes in protein length are also included in the present invention if the functional equivalence of human AAT of SEQ ID NO: 3 is maintained. For example, cleavage or elongation of protein length by up to 50, 40, 30, 20, or 10 amino acids may maintain AAT activity and are therefore included in the present invention.
[0139] Functionally similar sequences refer to sequences that encode a functional AAT gene product and enable the same or similar functional effects as human AAT. The function of AAT can be determined by its ability to inhibit various proteases in vitro, such as trypsin, or by its ability to inhibit neutrophil elastase (described below). Appropriate assays for determining protease activity or neutrophil elastase activity are known to those skilled in the art.
[0140] Protein modifications to AAT proteins that can occur through substitutions of amino acid sequences and nucleic acid sequences encoding such molecules are included within the scope of this invention. Substitutions as defined herein are modifications made to the amino acid sequence of a protein, thereby replacing one or more amino acids with the same number of (different) amino acids, resulting in a protein with a different amino acid sequence than the primary protein. In some embodiments, this modification does not significantly alter the function of the protein. Like additions, substitutions can be natural or artificial. It is well known in the art that amino acid substitutions can be made without significantly altering the function of a protein. This is especially true when the modification concerns “conservative” amino acid substitutions, i.e., replacing one amino acid with another amino acid having similar properties. Such “conservative” amino acids may be natural or synthetic amino acids that, due to their size, charge, polarity, and conformation, can be substituted without significantly affecting the structure and function of the protein. Many amino acids can be substituted with conservative amino acids without adversely affecting the function of the protein. Generally, the group of conserved amino acids consists of the nonpolar amino acids Gly, Ala, Val, Ile, Leu; the nonpolar aromatic amino acids Phe, Trp, Tyr; the neutral polar amino acids Ser, Thr, Cys, Gln, Asn, Met; the positively charged amino acids Lys, Arg, and His; and the negatively charged amino acids Asp and Glu. This list is not exhaustive. For example, it is well known that Ala, Gly, Ser, and sometimes Cys can be substituted for each other, even if they belong to different groups.
[0141] In other embodiments, the alpha-1 antitrypsin (AAT) protein can be replaced with other serine protease inhibitors. Therefore, any features relating to AAT disclosed herein may also apply to other serine protease inhibitors. In one embodiment, the serine protease inhibitor is a trypsin-like serine protease inhibitor.
[0142] Trypsin-like serine protease inhibitors inhibit serine proteases with trypsin-like activity. Serine functions as a nucleophilic amino acid at the active site of serine protease enzymes. Numerous trypsin-like serine proteases have been actively studied as therapeutic targets for inhibition. Viral entry via endocytosis depends on target cell proteases such as serine proteases.
[0143] If a virus requires target cell serine proteases for entry and replication, then viral infection is dependent on target cell serine proteases.
[0144] Target cell serine proteases activate viral spike proteins necessary for the fusion of the viral membrane with the target cell membrane and the release of the viral genome into the target cell cytosol. By targeting host cell serine proteases, endocytosis-dependent viral replication can be prevented, thus inhibiting target cell serine proteases is an effective method for treating subjects infected with endocytosis-dependent viruses. Serine protease inhibitors, preferably trypsin-like serine protease inhibitors, inhibit viral infection and replication. Non-exclusive examples of trypsin-like serine protease inhibitors include camostat, aprotinin, benzamidine, gabexate, leupeptin, nafamostat, pepstatin A, ribavirin, sepimostat, urinastatin, and patamostat.
[0145] Medical indications:
[0146] In one embodiment of the present invention, a pharmaceutical composition or combination described herein is provided for use in the treatment and / or prevention of viral infections and / or conditions associated with viral infections in a subject. Preferred viral infections or related diseases to be treated are those described herein.
[0147] As used herein, “viral infection” is caused by a pathogenic virus entering the body of an organism. The type of virus is preferably selected from the group consisting of adenovirus, coxsackievirus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpesvirus type 8, HIV, influenza virus, measles virus, mumps virus, human papillomavirus, poliovirus, rabies virus, respiratory syncytial virus (RSV), rubella virus, varicella-zoster virus, and SARS-CoV-2 virus. In one embodiment, the family of viruses is preferably selected from the group consisting of Adenoviridae, Picornaviridae, Herpesviridae, Picornaviridae, Hepadnaviridae, Flaviviridae, Herpesviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papillomaviridae, Picornaviridae, Rabviridae, Togaviridae, Herpesviridae, and Coronaviridae.
[0148] In one embodiment of the present invention, a pharmaceutical composition or combination according to the present invention described herein is provided for use in the treatment of a medical condition related to SARS coronavirus, wherein the medical condition related to SARS coronavirus is preferably COVID-19 or a respiratory illness related to SARS coronavirus.
[0149] As used herein, “patient” or “subject” may be a vertebrate. In the context of this invention, the term “subject” includes both humans and animals, in particular mammals and other living organisms.
[0150] In the present invention, "treatment" or "therapy" generally means obtaining a desired pharmacological and / or physiological effect. This effect may be preventive, for example, by reducing the risk that the subject will have the disease or symptoms, in the sense of completely or partially preventing the disease and / or symptoms, or it may be therapeutic, in the sense of partially or completely curing the disease and / or side effects of the disease.
[0151] In the present invention, “treatment” includes any treatment of a disease or condition in a mammal, particularly a human, such as the following treatments (a) to (c): (a) prevention of the onset of the patient’s disease, condition, or symptoms; (b) suppression of symptoms, i.e., prevention of the progression of symptoms; (c) improvement of symptoms of a condition, i.e., induction of regression of the disease or symptoms.
[0152] In one embodiment, the treatment described herein relates to reducing or inhibiting coronavirus infection or its symptoms by preventing the entry of the virus into target cells. The prophylactic therapies described herein are intended to encompass the prevention or reduction of the risk of coronavirus infection by reducing the likelihood of cell infection with coronavirus through interaction with the ACE2 protein after treatment with the agents described herein.
[0153] As used herein, “patient with symptoms of infection” refers to a subject exhibiting one or more of the following symptoms: fever, diarrhea, fatigue, muscle pain, cough, difficulty breathing after an animal bite, severe headache with fever, rash or swelling, fever of unknown cause or prolonged fever or vision problems. Other symptoms include fever and chills, extreme hypothermia, decreased urine output (oliguria), rapid pulse, rapid respiration, nausea, and vomiting. In a preferred embodiment, the symptoms of infection are fever, diarrhea, fatigue, muscle pain, rapid pulse, rapid respiration, nausea and vomiting, and / or cough.
[0154] As used herein, patients with “symptoms of a viral infection of the respiratory tract” include, but are not limited to, those exhibiting one or more of the following symptoms of a cold or influenza-like illness: fever, cough, runny nose, sneezing, sore throat, difficulty breathing, headache, muscle aches, fatigue, increased pulse, rapid breathing, nausea and vomiting, loss of taste and / or smell, and / or malaise (feeling unwell).
[0155] In some embodiments, symptoms of SARS virus infection include fever, sore throat, cough, muscle aches, or fatigue, and in some embodiments, sputum, headache, hemoptysis, and / or diarrhea may occur. In some embodiments, symptoms of infection with SARS coronavirus (e.g., SARS-CoV-2) include fever, sore throat, cough, loss of taste and / or smell, shortness of breath, and / or fatigue.
[0156] As used herein, the term “patients at risk of developing severe acute respiratory syndrome (SARS)” refers to subjects at high risk (e.g., above average) of developing SARS, preferably subjects distinct from specific individuals within the general population. In some embodiments, the patient has symptoms of SARS or SARS coronavirus infection. In some embodiments, the patient does not have symptoms of SARS or SARS coronavirus infection. In some embodiments, the subject has been in contact with people who have SARS coronavirus infection or symptoms of SARS. In some embodiments, the person at risk of developing SARS has been tested for the presence of SARS coronavirus infection. In some embodiments, the person at risk of developing SARS has tested positive for SARS coronavirus infection, preferably coronavirus infection.
[0157] In embodiments, patients at risk of developing SARS are asymptomatic patients who have not yet shown the characteristic symptoms of SARS. Asymptomatic patients may be at risk of developing SARS because they have had contact with someone infected with the SARS coronavirus. For example, an asymptomatic patient may be identified as at risk of developing SARS by a software application (app) installed on a smartphone or corresponding (portable) device, which indicates physical proximity or closeness to an infected person using a corresponding app on the respective mobile phone / smartphone. Other methods for determining contact / physical proximity to an infected person are known to those skilled in the art and are similarly applicable to the methods of the present invention.
[0158] In some embodiments, patients who have or are at risk of developing severe acute respiratory syndrome (SARS) are infected with the coronavirus.
[0159] Coronaviruses are a group of related viruses that cause disease in mammals and birds. The scientific name for coronaviruses is Orthocoronavirinae or Coronavirae. Coronaviruses belong to the family Coronaviridae. This family is divided into the subfamilies Coronavirinae and Torovirinae, and further classified into six genera: alphacoronaviruses, betacoronaviruses, gammacoronaviruses, deltacoronaviruses, toroviruses, and baffiniviruses. Viruses of the genera Alphacoronavirus and Betacoronavirus primarily infect mammals, gammacoronaviruses infect birds, and viruses of the genus Deltacoronavirus have been found in both mammalian and avian hosts.
[0160] In humans, coronaviruses can cause mild respiratory infections such as the common cold, or more severe respiratory infections such as SARS, MERS, and COVID-19, which can be fatal. Coronaviruses are enveloped viruses with a positive-straightened single-stranded RNA genome and a helically symmetric nucleocapsid. The genome size of coronaviruses ranges from approximately 27 to 34 kilobases, making them the largest of all known RNA viruses.
[0161] Various species of human coronaviruses are known, for example, but are not limited to these, including human coronavirus OC43 (HCoV-OC43) of the β-CoV genus, human coronavirus HKU1 (HCoV-HKU1) of the β-CoV genus, human coronavirus 229E (HCoV-229E) of the α-CoV genus, human coronavirus NL63 (HCoV-NL63) of the α-CoV genus, Middle East Respiratory Syndrome-related coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
[0162] The risk factors for coronaviruses vary greatly. Some (such as MERS-CoV) can kill more than 30% of infected individuals, while others are relatively harmless, like the common cold. Coronaviruses cause the common cold, primarily with symptoms such as fever and sore throat due to swollen adenoids, and are most prevalent from winter to early spring. Coronaviruses can cause pneumonia (either direct viral or secondary bacterial pneumonia) and bronchitis (either direct viral or secondary bacterial bronchitis). Coronaviruses can also cause SARS.
[0163] Advances in nucleic acid sequencing technology (commonly known as next-generation sequencing, or NGS) have provided large-scale sequence data from various biological samples, enabling the characterization of both known and novel viral strains. Therefore, established methods are available for determining coronavirus infection.
[0164] Composition and Dosage:
[0165] According to the present invention, the administration of the composition may preferably be performed topically and / or locally to the mucosal surface of the target airway and / or oral cavity. "Topical administration" means applying the drug locally to a specific area of the skin, mucosal surface, or other tissue so that the drug exerts its effect on the surface and / or underlying tissue. "Local administration" means administration to a specific, limited area, preferably by topical administration.
[0166] As used herein, the “airway” is generally considered to consist of the nose, pharynx, larynx, trachea, and lungs and their various compartments. The airway is involved in the mammalian respiratory process, is part of the respiratory system, and is lined with respiratory mucosa or respiratory epithelium.
[0167] As used herein, “mucosal surface” is characterized by the presence of a covering mucosal fluid, such as saliva, tears, nasal mucus, gastric mucus, cervical mucus, or bronchial mucus, whose function includes supplying and delivering a range of immunomodulatory and healing-promoting species, including growth factors, antimicrobial proteins, and immunoglobulins.
[0168] As used herein, “medicinal excipients” essentially means anything other than the active pharmaceutical ingredient in a composition.
[0169] In the formulation of pharmaceutical compositions, excipients are typically added along with the active pharmaceutical ingredient for the following reasons: 1) to protect, support, or enhance the stability of the formulation; 2) to bulk up the formulation to help formulate the correct dosage form, in the case of potent drugs; 3) to improve patient acceptability; 4) to help improve the bioavailability of the active drug; and 5) to enhance the overall safety and efficacy of the formulation during storage and use.
[0170] Excipients used in the formulation of pharmaceutical compositions are further classified into various functional categories depending on the role they intend to play in the resulting formulation. Some excipients can have different functional roles in different formulation types, and furthermore, individual excipients can have different grades, types, and sources depending on their different functional roles. Possible types of excipients commonly used in the formulation of pharmaceutical suspensions include solvents / vehicles, cosolvents, buffers, preservatives, antioxidants, humectants / surfactants, antifoamers, flocculants, suspending agents / viscosity modifiers, flavorings, sweeteners, colorants, humectants, and chelating agents.
[0171] As used herein, “cryopreservation” is the process of preserving organelles, cells, tissues, extracellular matrix, organelles, or other biological constructs susceptible to damage caused by uncontrolled chemical reaction rates by freezing to very low temperatures (typically -20°C to -80°C using solid carbon dioxide, and sometimes down to -196°C using liquid nitrogen). At sufficiently low temperatures, any enzymatic or chemical activity that could damage the biological material in question is effectively stopped. Cryopreservation methods aim to reach low temperatures without causing further damage due to the formation of ice crystals during freezing.
[0172] As used herein, “aerosol” is a suspension of liquid and solid particles produced by an aerosol generator, such as a small volume nebulizer (SVN), a pressurized metered-dose inhaler (pMDI), or a dry powder inhaler (DPI). Aerosol deposition is the process by which aerosol particles accumulate on an absorbent surface.
[0173] Aerosol devices used in clinical settings produce heterogeneously dispersed (also called polydisperse) particle sizes, meaning that a variety of sizes are present in the aerosol. Specific sizes and / or size ranges are outlined in the above invention summary. Monodisperse aerosols consisting of a single particle size are rare. Polydisperse aerosols can be defined by their median mass diameter (MMD). This measurement determines the upper and lower particle sizes (in μm) that contain 50% of the particle's mass. This is the particle size that evenly divides the mass or amount of drug in the particle size distribution. Depending on the method of size measurement, this is usually given as the median mass aerodynamic diameter (or MMAD). A higher MMAD indicates a greater proportion of particle sizes with larger diameters.
[0174] Dry powder formulations offer advantages over liquid formulations, such as superior stability and the potential elimination of preservatives. Powders tend to adhere to the moist surface of the nasal mucosa before dissolving and being removed. The use of bioadhesive excipients or agents that slow ciliary action can reduce the clearance rate and improve absorption. Many factors, including hygroscopicity, solubility, particle size, particle shape, and flow properties, influence deposition and absorption.
[0175] Examples of dry powder nasal sprays:
[0176] SBNL Pharma (www.snbl.com) recently reported data from a Phase 1 study using a zolmitriptan powder cyclodextrin formulation (μco® system) for enhanced absorption, previously described in in vitro studies. Zolmitriptan was absorbed rapidly, and its relative bioavailability was higher than that of commercially available tablets and nasal sprays. The company has a capsule-based single-dose powder device (Fit-lizer) suitable for administering the powder formulation according to the present invention. Once inserted into the chamber, the top and bottom of the capsule are cut with sharp blades. The plastic chamber is compressed by hand, and compressed air passes through a one-way valve and the capsule during operation, releasing the powder.
[0177] Bespak (www.bespak.com) is similar to a Fit-lizer device, based on the Unidose-DPTM principle. An air-filled compartment is compressed until a pin punctures a membrane, releasing pressure and releasing a plume of powder. Delivery of a powder formulation of a model antibody (human IgG) has been tested in a nasal cast model based on human MRI imaging. Approximately 95% of the dose was delivered to the nasal cavity, but the majority did not deposit beyond the nasal vestibule, with only about 30% depositing in the deeper compartments of the nasal cavity.
[0178] Examples of dry powder inhalers:
[0179] AstraZeneca sells budesonide powder supplied in a Turbuhaler multi-dose inhaler, which has been improved for nasal inhalation (Rhinocort Turbuhaler®; www.az.com). In some markets, it is marketed as an alternative to liquid sprays for allergic rhinitis and nasal polyps.
[0180] The Aptar Group (www.aptar.com) offers a simple blister-based powder inhaler. Before use, the blister is punctured, and the device's nosepiece is placed in one nostril. The subject closes the other nostril with a finger and inhales the powder into the nose. A powder formulation of apomorphine for Parkinson's disease using a blister-based powder inhaler (BiDose® / Prohaler®) manufactured by Pfeiffer / Aptar is currently in clinical development by Britannia, a UK company recently acquired by Stada Pharmaceutical (www.stada.de). Such a dosing device is intended for administering the compositions described herein.
[0181] Examples of liquid formulation inhalers:
[0182] Inhalation solutions and suspensions are typically aqueous formulations containing therapeutically effective ingredients, and may also contain additional excipients. Water-based oral inhalation solutions and suspensions must be sterile. Inhalation solutions and suspensions are intended to be delivered to the lungs by oral inhalation to obtain local and / or systemic effects and are used in conjunction with a designated nebulizer. These medicines are recommended to be supplied in unit doses to prevent microbial contamination during use. The container sealing system for these medicines consists of a container and a sealed container and may include protective packaging such as foil covering.
[0183] For example, Amikacin Liposome Inhalation Suspension (ALIS; Arikayce®) is a liposome formulation of the aminoglycoside antibacterial agent amikacin. Administered via inhalation after spraying, the ALIS formulation is designed to facilitate targeted local drug delivery to the lungs while minimizing systemic exposure. Such administration devices are intended for administering the compositions described herein.
[0184] Examples of liquid nasal sprays:
[0185] Nasal spray dispensers are typically non-pressurized dispensers that deliver a spray containing a quantified amount of active ingredient. Dosages can be measured by the spray pump or pre-measured during manufacturing. Nasal spray units can be designed for unit doses or to dispense formulations containing the active ingredient in up to several hundred metered sprays. Nasal sprays are applied to the nasal cavity to obtain topical and / or systemic effects.
[0186] Liquid nasal sprays are primarily aqueous solutions, but suspensions and emulsions can also be delivered. Liquid formulations are considered particularly useful for topical applications, such as preventing dryness and scabs that often accompany chronic nasal diseases through humidification.
[0187] For example, dispensers available from companies such as Nemera (La Verpilliere, France) or Aptar Pharma (Illinois, USA) are preferred. For instance, Nemera offers the Advancia® nasal spray dispenser, a high-performance pump with excellent dosage consistency and prime retention, an anti-clogging actuator, no metal contact with the formulation, and a hygienic anti-actuated snap-on overcap. As a further example, Aptar Pharma's nasal pump technology eliminates the need for pharmaceutical companies to add preservatives to nasal spray formulations. Advanced Preservative-Free (APF) systems prevent formulation contamination using tip seal and filter technology. A spring-loaded tip seal mechanism is employed along with a filter membrane within the ventilation channel.
[0188] Measuring and spray generation (e.g., orifices, nozzles, jets, etc.) pump mechanisms and components are used for the reproducible delivery of the formulation, and these can be constructed with many parts of various designs, precisely controlled in terms of dimensions and configuration. Energy is required to disperse the formulation as a spray. This is usually achieved by forcing the formulation through a nasal actuator and its opening. The formulation and the container sealing system (container, sealed container, pump, and any protective packaging) collectively constitute the pharmaceutical product. The design of the container sealing system affects the drug administration performance.
[0189] In some embodiments, the multi-use dispenser employs a membrane (preferably made of silicone) to prevent bacteria and viruses from entering the reservoir and pumping device. In some embodiments, the multi-use dispenser employs a metal-free fluid path to prevent oxidation of the formulation. In some embodiments, the multi-use dispenser employs a spring-loaded tip sealing mechanism to prevent microorganisms from entering the device during spray events.
[0190] In some embodiments, the dispenser is configured for multiple individual spray events of 5 to 1000 μL, preferably 5 to 500 μL, more preferably 10 to 300 μL, and more preferably 20 to 200 μL.
[0191] In some embodiments, the dispenser contains a total volume of 0.1 to 500 mL, preferably 1 to 100 mL, more preferably 2 to 50 mL, for example, about 5, 10, or 15 mL of the composition.
[0192] Examples of liquid throat sprays:
[0193] Bona (ShenZhen, China) is a supplier of medical packaging materials and complements. The company offers a product line of long-neck sprays that provide superior distribution and administration, designed for throat sprays and other treatments that require targeting the throat.
[0194] The dispenser arm rotates 360 degrees for ease of use by consumers. The spray is suitable not only for treating sore throats with medication but also for other treatments that provide topical care, such as protecting the throat from viral infections. The dispenser is preferably made of pharmaceutical-grade PP and PE, and can be combined with bottles of any size. Currently, nebulizers are available in a variety of common sizes (18 / 410, 18 / 415, 20 / 410, 24 / 410) and can be set to dispense from 220 microliters to 50 microliters.
[0195] Drug combinations:
[0196] The present invention relates to pharmaceutical compositions, and in other embodiments to pharmaceutical combinations. According to the present invention, a "pharmaceutical combination" preferably relates to the presence of a combination of extracellular vesicles derived from MSCs and AAT proteins, or to the use of two components in combination administration. In one embodiment, this combination is suitable for concomitant administration.
[0197] In one embodiment, the pharmaceutically acceptable combination described herein is characterized in that extracellular vesicles derived from MSCs are present in a pharmaceutical composition mixed with a pharmaceutically acceptable carrier, and AAT is present in a separate pharmaceutical composition mixed with a pharmaceutically acceptable carrier. Thus, the pharmaceutically acceptable combination of the present invention may, in some embodiments, involve the presence of two separate compositions or dosage forms located in close proximity to each other. The combined agents do not need to be present in a single composition.
[0198] In one embodiment, the pharmaceutically acceptable combination described herein is characterized in that the extracellular vesicles derived from MSCs and the AAT protein described herein are present in a kit in spatially adjacent but separate containers and / or compositions. The manufacture of the kit is within the capabilities of those skilled in the art. In one embodiment, separate compositions containing two separate agents may be packaged together and sold as a combination. In other embodiments, providing two agents in combination in separate packages, such as in a single catalog, is understood as a combination.
[0199] In one embodiment, the pharmaceutically acceptable combination described herein is characterized in that extracellular vesicles derived from MSCs and the AAT protein described herein are combined in a single pharmaceutical composition by mixing them with a pharmaceutically acceptable carrier. Combination formulations or compositions are known to those skilled in the art who can evaluate suitable carrier materials and formulation forms appropriate for both agents in the combination.
[0200] Concomitant administration:
[0201] According to the present invention, the term “combined administration,” also known as simultaneous administration or co-treatment, encompasses several embodiments in which the administration of separate formulations of the compounds disclosed herein allows for simultaneous treatment of each other, within minutes, at the same time, on the same day, in the same week, or in the same month. Alternating administration of two drugs is considered one embodiment of combined administration. Staggered administration is encompassed within the term combined administration, such as administering one drug, followed by a second drug, and possibly the first drug again. Simultaneous administration of multiple drugs is considered one embodiment of combined administration. In some embodiments, simultaneous administration encompasses oral ingestion, for example, by taking multiple compositions containing multiple drugs at the same time, or by taking separate tablets at the same time. Combination agents, such as single formulations containing multiple drugs disclosed herein and optionally additional anticancer agents, may also be used to co-administer various components in single doses or in doses.
[0202] Combination therapy or administration of a single drug may be performed concurrently with or before / after treatment with the other drug being used in combination, at intervals ranging from minutes to weeks. In embodiments where the second and first drugs are administered separately, it is generally important to ensure that there is not a significant time elapsed between each delivery so that the first and second drugs can combine to produce a synergistic effect favorably at the treatment site. In such examples, it is assumed that both modalities will come into contact with the target within approximately 12–24 hours of each other, more preferably within approximately 6–12 hours of each other, with a delay of only about 12 hours being the most preferable. In some situations, it may be desirable to significantly extend the treatment period, but each administration is spaced between several days (2, 3, 4, 5, 6, or 7 days) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8 days).
[0203] In the sense of the present invention, any form of administration of the multiple agents described herein is encompassed by concomitant administration, and beneficial additional therapeutic effects, preferably synergistic effects, are achieved through the concomitant administration of the two agents.
[0204] Synergistic effect:
[0205] In some embodiments, the combination of MSC-derived extracellular vesicles and AAT protein produces a synergistic effect.
[0206] Numerous models can be used to determine or quantify the degree of synergistic or antagonistic effects obtained by any given combination. Typically, a synergistic effect is considered to be an effect of a magnitude exceeding the sum of the two known effects. In some embodiments, the combined reaction is compared to the expected combined reaction under the assumption of non-interaction, calculated using a reference model (see Tang J. et al. (Tang, Wennerberg, and Aittokallio 2015)).
[0207] Commonly used reference models include the best single-agent (HSA) model (Berenbaum 1989), the Loewe additive model (LOEWE 1953), the Bliss independent model (BLISS 1939), and more recently, the zero-interaction potency (ZIP) model (Yadav et al. 2015). Because the assumptions made in these reference models differ from one another, somewhat inconsistent conclusions may be drawn regarding the degree of synergy. Nevertheless, according to the present invention, if any of these models demonstrate a synergistic effect between the drugs in the combination described herein, it can be assumed that a synergistic effect has been achieved. Preferably, two, three, or all four of these models reveal a synergistic effect between any two drugs in the combination described herein.
[0208] While not limiting, four reference models are recommended for their reliable results: (i) the HSA model, where the synergy score quantifies the excess over the best single-drug response; (ii) the Loewe model, where the synergy score quantifies the excess over the expected response when the two drugs are the same compound; (iii) the Bliss model, where the expected response is a multiplier effect as if the two drugs acted independently; and (iv) the ZIP model, where the expected response corresponds to an additive effect as if the two drugs did not affect each other's potency.
[0209] The most widely used criterion for combinations, and the recommended model for determining synergistic effects, is "Loewe additiveity," or the "Loewe model" (Loewe 1928; LOEWE 1953; Loewe and Muischnek 1926), or "dose additiveity," which explains the trade-off in potency between two drugs when the same compound is present on both sides of the dose matrix. For example, if 50% inhibition is achieved individually by 1 uM of drug A or 1 uM of drug B, then a combination of 0.5 uM of A and 0.5 uM of B should also achieve 50% inhibition. Synergistic effects beyond this level are particularly important when justifying the clinical use of a proposed combination therapy, as they define the point at which the combination can provide additional benefits beyond simply increasing the dose of either drug. [Brief explanation of the drawing]
[0210] The following figures are provided to illustrate specific embodiments of the present invention and are not intended to limit its scope.
[0211] [Figure 1] AAT is expressed from a transgene encoding AAT derived from genetically modified MSCs. [Figure 2] AAT expressed from recombinant MSCs and human plasma is equally potent in inhibiting neutrophil elastase. [Figure 3]Schematic diagram of in vivo experiments for the treatment of elastase-induced emphysema in a mouse model. [Figure 4-1] In vivo efficacy of MSCs transduced to express AAT in the treatment of elastase-induced emphysema in a mouse model. [Figure 4-2] Same as above [Figure 5] Lung tissue repair and regeneration were evaluated by histological analysis. [Modes for carrying out the invention]
[0212] The following examples are provided to illustrate specific embodiments of the present invention and are not intended to limit its scope. [Examples]
[0213] AAT expression from genetically modified MSCs:
[0214] Primary human MSCs derived from four healthy donors were transduced with an optimized retroviral construct (n = 36). Transduced cells were selected with puromycin and grown according to an established protocol. Proteins secreted from the genetically modified MSCs (including the morphology of secreted extracellular vesicles) were quantified in the cell culture supernatant by ELISA that specifically detects human AAT. AAT-MSCs averaged approximately 650 ng AAT / 1x10⁻¹⁶ at 48 hours. 5 Cells / VC are generated. The results are shown in Figure 1.
[0215] AAT expressed from recombinant MSCs and AAT expressed from human plasma:
[0216] The supernatant (including secreted extracellular vesicles) of transduced MSCs was incubated with neutrophil elastase, and then a fluorescent elastase substrate was added. Inhibition of neutrophil elastase by the supernatant resulted in reduced substrate hydrolysis and consequently, decreased RFU output. Natural full-length AAT derived from human serum was tested as a positive control. Supernatants from DMEM and untransduced MSCs served as negative controls. Transduced MSCs and human plasma-derived AAT were equally potent in inhibiting neutrophil elastase. The results are shown in Figure 2.
[0217] Transgenic AAT-expressing MSCs for the treatment of elastase-induced emphysema:
[0218] The in vivo efficacy of MSCs transduced to express AAT was evaluated in the treatment of elastase-induced emphysema in a mouse model. A schematic of the model is shown in Figure 3.
[0219] As shown in Figure 4, statistically significant improvements in five of the six lung function parameters were achieved by AAT-MSCs, not by native MSCs.
[0220] Lung tissue repair and regeneration were evaluated by histological analysis after treatment with unmodified MSCs or AAT-MSCs. As shown in Figure 5, significant lung tissue repair / regeneration was confirmed after two applications of AAT-MSCs.
[0221] summary:
[0222] As shown above, AAT is effectively expressed in MSCs from exogenous genes and exhibits activity similar to AAT isolated from human plasma. The therapeutic approach to the elastase-induced emphysema lung model described herein represents support for MSC-derived AAT expression and secretion, as well as the desirable anti-inflammatory properties achieved therein, particularly with respect to lung tissue.
[0223] Direct evaluation of the efficacy of isolated MSC extracellular vesicles in combination with AAT enriched or expressed from MSCs against viral infection is ongoing.
[0224] Drawing terminology AAT[ng / 1x10 5 cells / 48h / VCN] AAT[ng / 1x10 5 cells / 48 hours / VCN] Transduced MSCs NE Activity NE activity dam plasma human plasma Elastase 1st MSC application 2nd MSC application: Second MSC application Group group Treatment Cell dose / mouse Application volume applicable capacity cells / mouse [μL] cells / mouse [μL] Administration route Aminals / Group Animal / Group Saline (physiological saline solution) Oropharyngeal Forced Expiratory Volume Dynamic Compliance of Dynamic Semiconductors Forced Vital Capacity Chord compliance Inspiratory Capacity Vital Mini Lung Capacity Emphysema scoring Scoring
Claims
1. 1. A pharmaceutical composition comprising alpha-1 antitrypsin (AAT) protein for use as a medicament in the treatment and / or prevention of a viral infection in a human subject, said pharmaceutical composition being administered by inhalation.
2. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a solution containing the AAT protein.
3. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a suspension of solid drug particles.
4. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a dry powder, such as a micronized powder.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition is administered by introducing a therapeutically effective amount of the pharmaceutical composition into the nasal cavity, oral cavity or airways by inhaling and / or nebulizing a solution or suspension containing the AAT protein.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered by a nebulizer.
7. The pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered by a dispenser, either a pressurised metered dose inhaler or a dry powder inhaler.
8. The pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutical composition is administered by means of a nasal spray or oral spray dispenser.
9. The pharmaceutical composition of claim 1, wherein a solution of AAT is administered having a concentration of 10 to 500 mg of protein per 100 mL of solution.
10. 2. The pharmaceutical composition of claim 1, wherein the AAT protein comprises the sequence shown in SEQ ID NO:3 and / or is encoded by a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:
2.
11. 2. The pharmaceutical composition of claim 1, wherein the subject is suspected of having a viral infection and / or has had close proximity and / or contact with an individual with a viral infection.
12. The pharmaceutical composition according to any one of claims 1 to 9, which is administered prophylactically to a patient at risk of developing Severe Acute Respiratory Syndrome (SARS).
13. The pharmaceutical composition according to claim 11, wherein the virus of the viral infection is a coronavirus.
14. The pharmaceutical composition according to claim 11, wherein the virus of the viral infection is SARS-CoV-2.
15. The pharmaceutical composition of claim 11, wherein the virus of the viral infection is SARS-CoV-2 and the pharmaceutical composition is administered by a nebulizer.
